Literature DB >> 25634617

Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations.

Panagiotis Baliakas1, Andreas Agathangelidis2, Anastasia Hadzidimitriou3, Lesley-Ann Sutton1, Eva Minga4, Athina Tsanousa5, Lydia Scarfò2, Zadie Davis6, Xiao-Jie Yan7, Tait Shanafelt8, Karla Plevova9, Yorick Sandberg10, Fie Juhl Vojdeman11, Myriam Boudjogra12, Tatiana Tzenou13, Maria Chatzouli14, Charles C Chu7, Silvio Veronese15, Anne Gardiner6, Larry Mansouri1, Karin E Smedby16, Lone Bredo Pedersen11, Denis Moreno17, Kirsten Van Lom18, Véronique Giudicelli17, Hana Skuhrova Francova9, Florence Nguyen-Khac19, Panagiotis Panagiotidis13, Gunnar Juliusson20, Lefteris Angelis5, Achilles Anagnostopoulos21, Marie-Paule Lefranc17, Monica Facco22, Livio Trentin22, Mark Catherwood23, Marco Montillo15, Christian H Geisler11, Anton W Langerak10, Sarka Pospisilova9, Nicholas Chiorazzi7, David Oscier6, Diane F Jelinek24, Nikos Darzentas25, Chrysoula Belessi14, Frederic Davi19, Paolo Ghia2, Richard Rosenquist1, Kostas Stamatopoulos26.   

Abstract

An unresolved issue in chronic lymphocytic leukemia (CLL) is whether IGHV3-21 gene usage, in general, or the expression of stereotyped B-cell receptor immunoglobulin defining subset #2 (IGHV3-21/IGLV3-21), in particular, determines outcome for IGHV3-21-utilizing cases. We reappraised this issue in 8593 CLL patients of whom 437 (5%) used the IGHV3-21 gene with 254/437 (58%) classified as subset #2. Within subset #2, immunoglobulin heavy variable (IGHV)-mutated cases predominated, whereas non-subset #2/IGHV3-21 was enriched for IGHV-unmutated cases (P = .002). Subset #2 exhibited significantly shorter time-to-first-treatment (TTFT) compared with non-subset #2/IGHV3-21 (22 vs 60 months, P = .001). No such difference was observed between non-subset #2/IGHV3-21 vs the remaining CLL with similar IGHV mutational status. In conclusion, IGHV3-21 CLL should not be axiomatically considered a homogeneous entity with adverse prognosis, given that only subset #2 emerges as uniformly aggressive, contrasting non-subset #2/IGVH3-21 patients whose prognosis depends on IGHV mutational status as the remaining CLL.
© 2015 by The American Society of Hematology.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25634617      PMCID： PMC4311230          DOI： 10.1182/blood-2014-09-600874

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  25 in total

1.  CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia.

Authors:  U Thunberg; A Johnson; G Roos; I Thörn; G Tobin; J Sällström; C Sundström; R Rosenquist
Journal:  Blood       Date:  2001-03-15       Impact factor: 22.113

2.  Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia.

Authors:  Gerard Tobin; Ulf Thunberg; Anna Johnson; Ingrid Thörn; Ola Söderberg; Magnus Hultdin; Johan Botling; Gunilla Enblad; Jan Sällström; Christer Sundström; Göran Roos; Richard Rosenquist
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

3.  V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia.

Authors:  Alexander Kröber; Till Seiler; Axel Benner; Lars Bullinger; Elsbeth Brückle; Peter Lichter; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

4.  Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations.

Authors:  Kostas Stamatopoulos; Chrysoula Belessi; Carol Moreno; Myriam Boudjograh; Giuseppe Guida; Tatjana Smilevska; Lynda Belhoul; Stefania Stella; Niki Stavroyianni; Marta Crespo; Anastasia Hadzidimitriou; Laurent Sutton; Francesc Bosch; Nikolaos Laoutaris; Achilles Anagnostopoulos; Emili Montserrat; Athanasios Fassas; Guillaume Dighiero; Federico Caligaris-Cappio; Hélène Merle-Béral; Paolo Ghia; Frédéric Davi
Journal:  Blood       Date:  2006-09-19       Impact factor: 22.113

5.  Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope.

Authors:  Gerard Tobin; Ulf Thunberg; Anna Johnson; Inger Eriksson; Ola Söderberg; Karin Karlsson; Mats Merup; Gunnar Juliusson; Juhani Vilpo; Gunilla Enblad; Christer Sundström; Göran Roos; Richard Rosenquist
Journal:  Blood       Date:  2003-02-13       Impact factor: 22.113

6.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

Authors:  R N Damle; T Wasil; F Fais; F Ghiotto; A Valetto; S L Allen; A Buchbinder; D Budman; K Dittmar; J Kolitz; S M Lichtman; P Schulman; V P Vinciguerra; K R Rai; M Ferrarini; N Chiorazzi
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

7.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

Authors:  T J Hamblin; Z Davis; A Gardiner; D G Oscier; F K Stevenson
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

8.  Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status.

Authors:  Mia Thorsélius; Alexander Kröber; Fiona Murray; Ulf Thunberg; Gerard Tobin; Andreas Bühler; Dirk Kienle; Emilia Albesiano; Rossana Maffei; Lan-Phuong Dao-Ung; James Wiley; Juhani Vilpo; Anna Laurell; Mats Merup; Göran Roos; Karin Karlsson; Nicholas Chiorazzi; Roberto Marasca; Hartmut Döhner; Stephan Stilgenbauer; Richard Rosenquist
Journal:  Blood       Date:  2005-11-29       Impact factor: 22.113

9.  Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene.

Authors:  Paolo Ghia; Kostas Stamatopoulos; Chrysoula Belessi; Carol Moreno; Stefania Stella; Giuseppe Guida; Ariane Michel; Marta Crespo; Nikolaos Laoutaris; Emili Montserrat; Achilles Anagnostopoulos; Guillaume Dighiero; Athanasios Fassas; Federico Caligaris-Cappio; Frédéric Davi
Journal:  Blood       Date:  2004-10-05       Impact factor: 22.113

Review 10.  Chronic lymphocytic leukemia: revelations from the B-cell receptor.

Authors:  Freda K Stevenson; Federico Caligaris-Cappio
Journal:  Blood       Date:  2004-02-12       Impact factor: 22.113
View more
  30 in total

1.  Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8.

Authors:  Maria Gounari; Stavroula Ntoufa; Benedetta Apollonio; Nikos Papakonstantinou; Maurilio Ponzoni; Charles C Chu; Davide Rossi; Gianluca Gaidano; Nicholas Chiorazzi; Kostas Stamatopoulos; Paolo Ghia
Journal:  Blood       Date:  2015-04-21       Impact factor: 22.113

2.  Restrictions in the T-cell repertoire of chronic lymphocytic leukemia: high-throughput immunoprofiling supports selection by shared antigenic elements.

Authors:  A Vardi; E Vlachonikola; M Karypidou; E Stalika; V Bikos; K Gemenetzi; C Maramis; A Siorenta; A Anagnostopoulos; S Pospisilova; N Maglaveras; I Chouvarda; K Stamatopoulos; A Hadzidimitriou
Journal:  Leukemia       Date:  2016-11-25       Impact factor: 11.528

3.  Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification.

Authors:  Lesley-Ann Sutton; Anastasia Hadzidimitriou; Panagiotis Baliakas; Andreas Agathangelidis; Anton W Langerak; Stephan Stilgenbauer; Sarka Pospisilova; Zadie Davis; Francesco Forconi; Frederic Davi; Paolo Ghia; Richard Rosenquist; Kostas Stamatopoulos
Journal:  Haematologica       Date:  2017-06       Impact factor: 9.941

4.  ATM mutations in major stereotyped subsets of chronic lymphocytic leukemia: enrichment in subset #2 is associated with markedly short telomeres.

Authors:  Veronika Navrkalova; Emma Young; Panagiotis Baliakas; Lenka Radova; Lesley-Ann Sutton; Karla Plevova; Larry Mansouri; Viktor Ljungström; Stavroula Ntoufa; Zadie Davis; Gunnar Juliusson; Karin E Smedby; Chrysoula Belessi; Panagiotis Panagiotidis; Tasoula Touloumenidou; Frederic Davi; Anton W Langerak; Paolo Ghia; Jonathan C Strefford; David Oscier; Jiri Mayer; Kostas Stamatopoulos; Sarka Pospisilova; Richard Rosenquist; Martin Trbusek
Journal:  Haematologica       Date:  2016-06-16       Impact factor: 9.941

5.  Prognostic impact of epigenetic classification in chronic lymphocytic leukemia: The case of subset #2.

Authors:  Sujata Bhoi; Viktor Ljungström; Panagiotis Baliakas; Mattias Mattsson; Karin E Smedby; Gunnar Juliusson; Richard Rosenquist; Larry Mansouri
Journal:  Epigenetics       Date:  2016-04-29       Impact factor: 4.528

6.  Differences in prognosis of stereotyped IGHV3-21 chronic lymphocytic leukaemia according to additional molecular and cytogenetic aberrations.

Authors:  S Jeromin; C Haferlach; F Dicker; T Alpermann; T Haferlach; W Kern
Journal:  Leukemia       Date:  2016-07-14       Impact factor: 11.528

7.  The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.

Authors:  Preetesh Jain; Graciela M Nogueras González; Rashmi Kanagal-Shamanna; Uri Rozovski; Nawid Sarwari; Constantine Tam; William G Wierda; Philip A Thompson; Nitin Jain; Rajyalakshmi Luthra; Andres Quesada; Gabriela Sanchez-Petitto; Alessandra Ferrajoli; Jan Burger; Hagop Kantarjian; Jorge Cortes; Susan O'Brien; Michael J Keating; Zeev Estrov
Journal:  Br J Haematol       Date:  2017-11-21       Impact factor: 6.998

8.  No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy.

Authors:  Panagiotis Baliakas; Mattias Mattsson; Anastasia Hadzidimitriou; Eva Minga; Andreas Agathangelidis; Lesley-Ann Sutton; Lydia Scarfo; Zadie Davis; Xiao-Jie Yan; Karla Plevova; Yorick Sandberg; Fie J Vojdeman; Tatiana Tzenou; Charles C Chu; Silvio Veronese; Larry Mansouri; Karin E Smedby; Véronique Giudicelli; Florence Nguyen-Khac; Panagiotis Panagiotidis; Gunnar Juliusson; Achilles Anagnostopoulos; Marie-Paule Lefranc; Livio Trentin; Mark Catherwood; Marco Montillo; Carsten U Niemann; Anton W Langerak; Sarka Pospisilova; Niki Stavroyianni; Nicholas Chiorazzi; David Oscier; Diane F Jelinek; Tait Shanafelt; Nikos Darzentas; Chrysoula Belessi; Frederic Davi; Paolo Ghia; Richard Rosenquist; Kostas Stamatopoulos
Journal:  Haematologica       Date:  2017-12-21       Impact factor: 9.941

9.  Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG).

Authors:  Sonia Jaramillo; Andreas Agathangelidis; Christof Schneider; Jasmin Bahlo; Sandra Robrecht; Eugen Tausch; Johannes Bloehdorn; Manuela Hoechstetter; Kirsten Fischer; Barbara Eichhorst; Valentin Goede; Michael Hallek; Hartmut Döhner; Richard Rosenquist; Paolo Ghia; Kostas Stamatopoulos; Stephan Stilgenbauer
Journal:  Haematologica       Date:  2019-12-26       Impact factor: 9.941

Review 10.  Antigen receptor stereotypy in chronic lymphocytic leukemia.

Authors:  K Stamatopoulos; A Agathangelidis; R Rosenquist; P Ghia
Journal:  Leukemia       Date:  2016-11-04       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.